Product Identification

Product Name

Mestinon

Synonyms

(1-Methylpyridin-1-ium-3-yl) N,N-dimethylcarbamate bromide
2-((1-Methylethyl)thio)ethanol
2-Propan-2-ylsulfanylethanol
3-(Dimethylcarbamyloxy)-1-methylpyridinium bromide
3-Hydroxy-1-methylpyridinium bromide dimethylcarbamate
Kalymin
Mestinon

CAS

101-26-8

CAS

40811-49-2

Formula

C5H12OS

Formula

C9H13BrN2O2

Molecular Weight

120.22

Molecular Weight

261.12

EINECS

202-929-9

EINECS

255-090-6

RTECS

UU5270000

RTECS Class

Drug; Reproductive Effector; Human Data

Merck

12,8161

Beilstein/Gmelin

1697233

Beilstein/Gmelin

3764573

Beilstein Reference

4-01-00-02432

Beilstein Reference

4-21-00-00415

Physical and Chemical Properties

Appearance

White or practically white, crystalline powder. Agreeable odor.

Solubility in water

Freely soluble

Melting Point

154 - 155

Boiling Point

88 (25 torr)

Density

0.9613 g/cm3 (20 C)

Usage

Medication.

Refractive Index

1.48 (20 C)

First Aid Measures

Ingestion

Never induce vomiting unless directed by medical personnel. Never give anything by mouth to an unconscious person. Obtain medical assistance.

Ingestion

Seek medical assistance.

Inhalation

TOXIC; inhalation, ingestion, or skin contact with material may cause severe injury or death. Effects of contact or inhalation may be delayed.

Inhalation

Remove to fresh air. Give CPR, oxygen if needed.

Inhalation

Move victim to fresh air. Apply artificial respiration if victim is not breathing. Do not use mouth-to-mouth method if victim ingested or inhaled the substance; induce artificial respiration with the aid of a pocket mask equipped with a one-way valve or other proper respiratory medical device. Administer oxygen if breathing is difficult.

Skin

Immediately wash with soap and water.

Skin

Remove and isolate contaminated clothing and shoes. Immediately flush with running water for at least 20 minutes. For minor skin contact, avoid spreading material on unaffected skin.

Skin

Contact with molten substance may cause severe burns to skin and eyes. See Inhalation.

Eyes

Flush with water for 15 minutes.

Eyes

Immediately flush with running water for at least 20 minutes.

Eyes

See Inhalation.

Handling and Storage

Storage

Keep in a cool, dry location in a tightly closed container when not in use.

Handling

All chemicals should be considered hazardous. Avoid direct physical contact. Use appropriate, approved safety equipment. Untrained individuals should not handle this chemical or its container. Handling should occur in a chemical fume hood.

Hazards Identification

Ingestion

See Inhalation.

Inhalation

Excess secretions in the tracheal tree, bronchospasm, and pulmonary edema may occur.

Skin

Dermatitis, urticaria and reversible alopecia have been reported.

Eyes

Constriction of the pupil, blurred vision, and excessive secretions in the nose and throat may be present.

Ingestion

Cramping, abdominal pain, hyperperistalsis, vomiting, and diarrhea have been described.

Hazards

When heated, vapors may form explosive mixtures with air: indoors, outdoors, and sewers explosion hazards.

EC Risk Phrase

R 20/21/22

EC Safety Phrase

S 23 36/37

UN (DOT)

2810

Exposure Controls/Personal Protection

Personal Protection

Plastic/rubber gloves, safety goggles and disposable coveralls.

Personal Protection

Wear appropriate protective gloves, clothing and goggles.

Respirators

Wear positive pressure self-contained breathing apparatus (SCBA).

Respirators

Half face, negative pressure air purifying, dust/mist/fume efficiency filter respirator. Supplied air, full facepiece respirator.

Exposure Effects

Abnormally low blood pressure may occur from peripheral actions. However, elevated blood pressure may also be seen secondary to the anxiety resulting from the effects on other organ systems. Likewise, bradyarrhythmias are common from the antimyasthenics, but rapid heart rate may occur secondary to the anxiety resulting from the effects on other organ systems. Respiratory rate may be increased in patients with airway compromise. seizures and coma have been described; profound weakness and muscle fasciculations may also occur. In less severe cases, headache, dizziness, and dysarthria may occur. Parkinsonian-like symptoms have been reported during therapeutic use of pyridostigmine.

Fire Fighting Measures

Fire Fighting

Extinguish with water, carbon dioxide, dry chemical or foam. Wear NIOSH/MSHA approved, positive pressure SCBA and full protective turn out gear.

Fire Fighting

Small Fires: Dry chemical, carbon dioxide or water spray. Large Fires: Dry chemical, carbon dioxide, alcohol-resistant foam or water spray.

Fire Potential

Combustible material: may burn but does not ignite readily.

Accidental Release Measures

Small spills/leaks

ELIMINATE all ignition sources. Do not touch damaged containers or spilled material unless wearing appropriate protective clothing. Stop leak if you can do it without risk. Absorb or cover with dry earth, sand or other non-combustible material and transfer to containers. DO NOT GET WATER INSIDE CONTAINERS.

Small spills/leaks

Scoop/shovel material into a suitably labeled drum. Secure drum cover and move container to a safe holding area.

Stability and Reactivity

Stability

Stable at normal temperatures and pressures in in a tightly sealed container.

Decomposition

Oxides of carbon, oxides of nitrogen, hydrogen bromide and brominated compounds.

Combustion Products

Fire may produce irritating, corrosive and/or toxic gases.

Transport Information

UN Number

2810